114
Participants
Start Date
October 15, 2015
Primary Completion Date
March 22, 2017
Study Completion Date
March 22, 2017
Rivaroxaban
Participants will receive Rivaroxaban 15 milligram (mg) twice daily up to Days 21 by orally and Rivaroxaban 20 mg once daily up to Days 90 by orally.
Standard-of-care
Standard-of-care as per local protocol and defined by the medical team caring for the participant.
Montgomery
Chandler
Phoenix
Tucson
Los Angeles
Sacramento
Sylmar
New Haven
Washington D.C.
Pensacola
Tampa
Davenport
Iowa City
Baltimore
Springfield
Detroit
Jackson
Lansing
Royal Oak
St Louis
Atlantic City
Camden
Brooklyn
Buffalo
New York
Stony Brook
Chapel Hill
Charlotte
Durham
Winston-Salem
Cincinnati
Cleveland
Toledo
Zanesville
Portland
Allentown
Bethlehem
Philadelphia
Pittsburgh
West Reading
Charleston
Dallas
Fort Worth
Houston
Salt Lake City
Charlottesville
Bellingham
Everett
Spokane
Tacoma
Collaborators (1)
Bayer
INDUSTRY
Janssen Scientific Affairs, LLC
INDUSTRY